Sign In
Buy ASH
Ashland Earnings Calls
| Release date | Nov 04, 2025 |
| EPS estimate | $1.17 |
| EPS actual | $1.08 |
| EPS Surprise | -7.69% |
| Revenue estimate | 397.071M |
| Revenue actual | 478M |
| Revenue Surprise | 20.38% |
| Release date | Jul 29, 2025 |
| EPS estimate | $1.15 |
| EPS actual | $1.04 |
| EPS Surprise | -9.57% |
| Revenue estimate | 482.634M |
| Revenue actual | 463M |
| Revenue Surprise | -4.07% |
| Release date | Apr 30, 2025 |
| EPS estimate | $1.10 |
| EPS actual | $0.99 |
| EPS Surprise | -10.00% |
| Revenue estimate | 491.221M |
| Revenue actual | 479M |
| Revenue Surprise | -2.49% |
| Release date | Jan 28, 2025 |
| EPS estimate | $0.790 |
| EPS actual | $0.280 |
| EPS Surprise | -64.56% |
| Revenue estimate | 426.988M |
| Revenue actual | 405M |
| Revenue Surprise | -5.15% |
Last 4 Quarters for Ashland
Below you can see how ASH performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Jan 28, 2025 |
| Price on release | $71.16 |
| EPS estimate | $0.790 |
| EPS actual | $0.280 |
| EPS surprise | -64.56% |
| Date | Price |
|---|---|
| Jan 22, 2025 | $70.63 |
| Jan 23, 2025 | $71.95 |
| Jan 24, 2025 | $71.07 |
| Jan 27, 2025 | $71.14 |
| Jan 28, 2025 | $71.16 |
| Jan 29, 2025 | $64.17 |
| Jan 30, 2025 | $63.74 |
| Jan 31, 2025 | $63.49 |
| Feb 03, 2025 | $60.89 |
| 4 days before | 0.750% |
| 4 days after | -14.43% |
| On release day | -9.82% |
| Change in period | -13.79% |
| Release date | Apr 30, 2025 |
| Price on release | $54.39 |
| EPS estimate | $1.10 |
| EPS actual | $0.99 |
| EPS surprise | -10.00% |
| Date | Price |
|---|---|
| Apr 24, 2025 | $53.38 |
| Apr 25, 2025 | $53.12 |
| Apr 28, 2025 | $53.41 |
| Apr 29, 2025 | $53.48 |
| Apr 30, 2025 | $54.39 |
| May 01, 2025 | $49.03 |
| May 02, 2025 | $49.43 |
| May 05, 2025 | $49.69 |
| May 06, 2025 | $48.14 |
| 4 days before | 1.89% |
| 4 days after | -11.49% |
| On release day | -9.85% |
| Change in period | -9.82% |
| Release date | Jul 29, 2025 |
| Price on release | $50.18 |
| EPS estimate | $1.15 |
| EPS actual | $1.04 |
| EPS surprise | -9.57% |
| Date | Price |
|---|---|
| Jul 23, 2025 | $52.70 |
| Jul 24, 2025 | $50.71 |
| Jul 25, 2025 | $51.26 |
| Jul 28, 2025 | $50.95 |
| Jul 29, 2025 | $50.18 |
| Jul 30, 2025 | $52.98 |
| Jul 31, 2025 | $51.56 |
| Aug 01, 2025 | $50.50 |
| Aug 04, 2025 | $50.76 |
| 4 days before | -4.78% |
| 4 days after | 1.16% |
| On release day | 5.58% |
| Change in period | -3.68% |
| Release date | Nov 04, 2025 |
| Price on release | $47.84 |
| EPS estimate | $1.17 |
| EPS actual | $1.08 |
| EPS surprise | -7.69% |
| Date | Price |
|---|---|
| Oct 29, 2025 | $49.64 |
| Oct 30, 2025 | $48.67 |
| Oct 31, 2025 | $48.90 |
| Nov 03, 2025 | $48.23 |
| Nov 04, 2025 | $47.84 |
| Nov 05, 2025 | $50.74 |
| Nov 06, 2025 | $50.29 |
| Nov 07, 2025 | $50.05 |
| Nov 10, 2025 | $49.89 |
| 4 days before | -3.63% |
| 4 days after | 4.29% |
| On release day | 6.06% |
| Change in period | 0.504% |
Ashland Earnings Call Transcript Summary of Q3 2025
Ashland reported Q3 FY2025 results with resilient margins and strong cash conversion despite softer-than-expected volumes. Sales were $463M, down 15% year-over-year (5% organically), and adjusted EBITDA was $113M (24.4% margin). Management completed portfolio optimization and is ahead of schedule on restructuring, continuing a $60M manufacturing optimization program (HEC consolidation completed). Life Sciences and Personal Care showed pockets of growth and strong margins (Life Sciences ~33%), while Specialty Additives and Intermediates faced headwinds—notably weak coatings demand and China overcapacity. The company recorded a noncash goodwill impairment of $706M (does not affect liquidity or operations). Liquidity remained strong (>$800M) with net leverage ~2.9x and nearly 100% free cash flow conversion in Q3. Ashland narrowed FY25 guidance to sales of $1.825B–$1.85B and adjusted EBITDA of $400M–$410M, taking a prudent stance given muted near-term demand while emphasizing cost actions, innovation progress (already $10M incremental innovation sales YTD) and long-term confidence in growth catalysts.
